Identifying Molecular Predictive Biomarkers for Available Chemotherapy and Targeted Therapy for Lung Cancer
We have assembled a large dataset of drug response phenotypes for ~100 NSCLC cell lines to drugs already used for lung cancer treatment. We have identified important subsets (10-20 percent) of lung cancers that are very sensitive to these therapies compared to others that are 1000-fold more resistant.
We are integrating this with our genome-wide information in mRNA expression, copy number variation, DNA methylation, proteomics, and whole exome mutation analyses to identify molecular biomarkers predictive of response to these clinically available drugs. This provides a preclinical platform for developing and testing new lung cancer therapies and also a method for developing molecular “enrollment biomarkers” that can be used in clinical trials.
